Legend Biotech's CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma -April 05, 2024 at 11:31 pm EDT
New indication for this one-time infusion may provide patients with a treatment-free respite as early as first relapse ...
Source: marketscreener.com